Mikhail Savitski, Team Leader and Head of Proteomics Core Facility at EMBL - “To me the combination of CETSA with mass spectrometry is the most exciting thing that has happened in drug discovery and proteomics in a long time.”

Mike Snowden, Vice President Discovery Sciences at AstraZeneca - “CETSA is an exciting technology that will allow us to examine the interaction between a drug candidate and its protein target within the cell. We are pleased to be exploring the potential of this platform in an open collaboration with the scientists at Pelago.”

Mark Bunnage, Previously Vice President, Worldwide Medicinal Chemistry at Pfizer - “We believe that the CETSA method may hold promise within our research at Pfizer, and we look forward to working with our counterparts at Pelago.”

Review Article on CETSA®